CRANBURY, N.J., Feb. 12, 2018 (GLOBE NEWSWIRE) — Amicus Therapeutics (Nasdaq:FOLD) today announced that the U.S. Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for filing under priority review for the oral precision…Original Article
U.S. FDA Files New Drug Application Under Priority Review for Migalastat for Treatment of Fabry Disease
